<H1>Chapter DOI: 10.1208/aapsj070355<br/>Cited-By Count: 77</H1><table border="1" width="30%"><tr><td>Total References</td><td>28</td></tr><tr><td>Springer references</td><td>7</td></tr><tr><td>Non Springer references</td><td>21</td></tr><tr><td>BibStructured Count</td><td width="10%">22</td></tr><tr><td>BibUnstructured Count</td><td width="10%">6</td></tr><tr><td>DOI already available in SpringerLink</td><td>15</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>2</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>2</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>4</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>3</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>1</td></tr><tr><td>Valid DOI Enriched</td><td>2</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Sheiner LB. Learning versus confirming in clinical drug development.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1997;61:275&#8211;291.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(97)90160-0>10.1016/S0009-9236(97)90160-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibBook</td><td>Kimko HC, Duffull SB, eds. Simulation for Designing Clinical Trials.<Emphasis Type="Italic">A Pharmacokinetic-Pharmacodynamic Modeling Perspective</Emphasis>. New York: Marcel Dekker; 2003.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1201/9780203910276>10.1201/9780203910276</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle</td><td>CrossRef</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 1994;34:111&#8211;119.</td><td><a href=http://dx.doi.org/10.1002/j.1552-4604.1994.tb03974.x>10.1002/j.1552-4604.1994.tb03974.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Year, Author_FamilyName_1, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Galluppi GR, Rogge MC, Roskos LK, et al. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2001;69:387&#8211;399.</td><td><a href=http://dx.doi.org/10.1067/mcp.2001.115455>10.1067/mcp.2001.115455</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Lesko LJ, Rowland M, Peck CC, Blaschke TF. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2000;17:1335&#8211;1344.</td><td><a href=http://dx.doi.org/10.1023/A:1007574217260>10.1023/A:1007574217260</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development.<Emphasis Type="Italic">Annu Rev Pharmacol Toxicol</Emphasis>. 2000;40:67&#8211;96.</td><td><a href=http://dx.doi.org/10.1146/annurev.pharmtox.40.1.67>10.1146/annurev.pharmtox.40.1.67</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>U.S. Department of Health and Human Services, FDA. Exposure-response relationships&#8212;study design</span>, <span style='background:#FFD9B3'>data analysis, and regulatory applications</span>. Available at: <span style='background:#FF3300'>http://www.fda.gov/cder/gdlns/exposure.htm</span>. Accessed May 9, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Holford</span> <span style='background:#DDDDDD'>NHG</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hale</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ko</span> <span style='background:#DDDDDD'>HC</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Steimer</span> <span style='background:#DDDDDD'>J-L</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Sheiner</span> <span style='background:#DDDDDD'>LB</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Peck</span> <span style='background:#DDDDDD'>CC.</span></span></aug>, <span style='background:#FFD9B3'>Simulation in Drug Development: Good Practices</span>. Available at: <span style='background:#FF3300'>http://cdds.georgetown.edu/research/sddgp723.html</span>. Accessed May 9, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Holford NH, Kimko HC, Monteleone JP, Peck CC. Simulation of clinical trials.<Emphasis Type="Italic">Annu Rev Pharmacol Toxicol</Emphasis>. 2000;40:209&#8211;234.</td><td><a href=http://dx.doi.org/10.1146/annurev.pharmtox.40.1.209>10.1146/annurev.pharmtox.40.1.209</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Kimko HC, Reele SS, Holford NH, Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2000;68:568&#8211;577.</td><td><a href=http://dx.doi.org/10.1067/mcp.2000.110975>10.1067/mcp.2000.110975</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Gisleskog PO, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2002;29:473&#8211;505.</td><td><a href=http://dx.doi.org/10.1023/A:1022972420004>10.1023/A:1022972420004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Duffull SB, Mentr&#233; F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2001;18:83&#8211;89.</td><td><a href=http://dx.doi.org/10.1023/A:1011035028755>10.1023/A:1011035028755</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Retout S, Mentre F. Optimization of individual and population designs using S-PLUS.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2003;30:417&#8211;443.</td><td><a href=http://dx.doi.org/10.1023/B:JOPA.0000013000.59346.9a>10.1023/B:JOPA.0000013000.59346.9a</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Ette EI, Howie CA, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1995;12:729&#8211;737.</td><td><a href=http://dx.doi.org/10.1023/A:1016267811074>10.1023/A:1016267811074</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibChapter</td><td>Hutmacher MM, Kowalski KG. Evaluation of random sparse sampling designs for a population pharmacokinetic study: Assessment of power and bias using simulations. In: Kimko HC, Duffull SB, eds.<Emphasis Type="Italic">Simulation for Designing Clinical Trials. A Pharmacokinetic-Pharmacodynamic Modeling Perspective</Emphasis>. New York: Marcel Dekker; 2003.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Dantzig A, de Alwis DP, Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 2003;55:133&#8211;150.</td><td><a href=http://dx.doi.org/10.1016/S0169-409X(02)00175-8>10.1016/S0169-409X(02)00175-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Giaccone G, Linn SC, Welink J, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.<Emphasis Type="Italic">Clin Cancer Res</Emphasis>. 1997;3:2005&#8211;2015.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18</td><td>BibArticle</td><td>van Tellingen O, Kemper M, Beijnen JH. P-glycoprotein inhibition in tumors by PSC833: impact of dose adjustments on the efficacy of doxorubicin chemotherapy.<Emphasis Type="Italic">AACR</Emphasis>. 2001;42:950.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Callies S, de Alwis DP, Mehta A, Burgess M, Aarons L. Population pharmacokinetic model for daunorubucuin and daunorubicinol coadministered with zosuquidar. 3HCL (LY335979).<Emphasis Type="Italic">Cancer Chemother Pharmacol</Emphasis>. 2004;54:39&#8211;48.</td><td><a href=http://dx.doi.org/10.1007/s00280-004-0775-4>10.1007/s00280-004-0775-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979).<Emphasis Type="Italic">Cancer Chemother Pharmacol</Emphasis>. 2003;51:107&#8211;118.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Peck CC, Rubin DB, Sheiner LB. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2003;73:481&#8211;490.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(03)00018-3>10.1016/S0009-9236(03)00018-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Holford NHG, Coates PE, Guentert TW, Riegelman S, Sheiner LB. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration-effect relationships.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 1981;11:187&#8211;195.</td><td><a href=http://dx.doi.org/10.1111/j.1365-2125.1981.tb01123.x>10.1111/j.1365-2125.1981.tb01123.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, Year, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval.<Emphasis Type="Italic">Heart</Emphasis>. 2002;87:220&#8211;228.</td><td><a href=http://dx.doi.org/10.1136/heart.87.3.220>10.1136/heart.87.3.220</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2001;28:171&#8211;192.</td><td><a href=http://dx.doi.org/10.1023/A:1011555016423>10.1023/A:1011555016423</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>U.S. Department of Health and Human Services, FDA. Guidance for Industry</span>: <span style='background:#FFD9B3'>Population Pharmacokinetics</span>. Available at: <span style='background:#FF3300'>http://www.fda/gov/cder/guidance/1852fnl.pdf</span>. Accessed May 9, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-3-319-27883-4_4>10.1007/978-3-319-27883-4_4</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle</td><td>CrossRef</td></tr><tr><td>CR26</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Venitz</span> <span style='background:#DDDDDD'>J.</span></span></aug> Using exposure-response relationships to define a therapeutic index. Clinical Pharmacology Subcommittee for Pharmaceutical Science, US Department of Health and Human Services, FDA. ACPS Clinical Pharmacology Subcommittee Meeting October 23, <span style='background:#66FF66'>2002</span>. <span style='background:#C0FFC0'>Rockville, MD</span>, NTI-CPSC Presentation, October 23, 2002. Available at: <span style='background:#FF3300'>www.fda.gov/ohrms/dockets/ac/02/slides/</span> <span style='background:#FFFF0F'>3898S1_06_Venitz.pdf. Accessed May 9, 2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR27</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Stanski</span> <span style='background:#DDDDDD'>DR</span></span></aug>. <span style='background:#FFD9B3'>Model-Based Drug Development: A Critical Path Opportunity</span>. Available at: <span style='background:#FF3300'>http://www.fda.gov/oc/initiatives/criticalpath/stanski/stanski.html</span>. Accessed May 9, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>U.S. Department of Health and Human Services, FDA. Challenge and opportunity on the critical path to new medical products</span>. FDA, March <span style='background:#66FF66'>2004</span>. Available at: <span style='background:#FF3300'>http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html</span>. <span style='background:#FFFF0F'>Accessed May 9, 2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>